Tr is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.作用机制：It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. Tr was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.潜在的研究应用食欲控制和饱腹感研究血糖和胰岛素敏感性研究肥胖和代谢综合征模型GLP-1受体途径调节研究Tr mechanism of action: effects on endocrine function and insulin resistance in patients with type 2 diabetes. Tirpatide is a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is under investigation for use in chronic weight management, major adverse cardiovascular events, and the management of other conditions, including heart failure with preserved ejection fraction, obesity, and non-cirrhotic non-alcoholic steatohepatitis. The Phase 3 SURPASS 1-5 clinical trial programme was designed to assess the efficacy and safety of once-weekly subcutaneously injected tir (5, 10, and 15 mg), as monotherapy or combination therapy, across a broad spectrum of people with type 2 diabetes.Use of tir in clinical studies was associated with marked reductions in glycated haemoglobin (-1.87 to -2.59%, -20 to -28 mmol/mol) and body weight (-6.2 to -12.9 kg), as well as reductions in parameters commonly associated with heightened cardiometabolic risk such as blood pressure, visceral adiposity, and circulating triglycerides. In SURPASS-2, these reductions were greater than those with the GLP-1 receptor agonist se 1 mg. Tir was well tolerated, with a low risk of hypoglycaemia when used without insulin or insulin secretagogues, and showed a generally similar safety profile to the GLP-1 receptor agonist class. Accordingly, evidence from these clinical trials suggests that tr offers a new opportunity for the effective lowering of glycated haemoglobin and body weight in adults with type 2 diabetes.
产品展示
分析报告
客户反馈
工厂介绍
上海升升新材料有限公司是一家深耕生物多肽领域，专业从事多肽产品研发、生产、销售及全链条服务的国家高新技术企业。我们致力于以自主创新技术赋能健康美丽行业。核心定位与使命我们专注于核心生物多肽赛道，打造从原材料研发到最终用户应用的完整产业链，涵盖医药、功能食品及保健品、化妆品等多元化场景。Adhering to the philosophy of "Independent Technology, Quality First" and with the mission of "Making Biopeptides Benefit More People", we strive to promote "Chinese Peptides" to the global market.质量控制与市场布局我们严格执行全面的质量管理体系：从原材料采购、生产过程到产品检验的每一个环节都受到严格控制，确保产品的高质量和稳定性。全球市场布局：我们的产品销往多个国家和地区，赢得了全球客户的广泛认可和信任。坚持“质量第一、客户至上”的原则：以客户需求为中心，提供个性化产品定制和解决方案，满足多样化需求。如果您正在寻找可靠有效的解决方案来支持您的体重管理之旅，上海升尚新材料有限公司是您值得信赖的合作伙伴。请立即联系我们，详细了解我们的产品以及它们如何帮助您实现目标。
